Objectives: Antibiotic susceptibility of Legionella pneumophila is poorly understood, with treatment of Legionnaires' disease often based on empirical choice. The aim of this study was to determine the antibiotic susceptibility of L. pneumophila strains.
Introduction
The utility of antimicrobial susceptibility testing (AST) to guide treatment of respiratory infections caused by Legionella pneumophila is controversial; indeed clinical breakpoints to interpret results have never been formulated and standard disc diffusion methods are not considered appropriate to determine susceptibility. 1 Legionella spp. can cause severe pneumonia known as Legionnaires' disease (LD). Treatment of LD is based on empirical decisions rather than guided therapy and laboratories do not routinely test the susceptibility of Legionella isolates to antibiotics. In addition to the lack of routine testing, there are few historical data to ensure antibiotic selection is appropriate when treating LD. 2 b-Lactams are frequently used as a first-line treatment for patients with community-acquired pneumonia (CAP); therefore, understanding susceptibility to this group of antibiotics is useful to ensure routine regimens cover legionellosis. However, these agents are poorly effective against intracellular pathogens; therefore, agents able to reach therapeutic concentration within eukaryotic cells (e.g. macrolides, fluoroquinolones, rifampicin and cyclin families) should be used. 2 In the UK, once a diagnosis of LD has been made, recommended treatment consists of oral fluoroquinolones for low-to moderate-severity CAP and fluoroquinolones combined with a macrolide for high severity CAP. 3 Currently the mainstay treatment for LD is azithromycin or levofloxacin; both antibiotics are considered effective at treating this pathogen intracellularly.
MIC and epidemiological cut-off values to determine resistance are limited for L. pneumophila, mainly owing to the lack of a standardized methodology for AST. 4 Therefore, results from in vitro experiments are difficult to interpret. Interestingly, despite appropriate use of macrolides and/or fluoroquinolones, treatment failures have been reported in the literature. 5 Massip et al. 6 suggested that the presence of a macrolide induced the LpeAB efflux pump, which if overexpressed may give rise to increased tolerance to macrolides in L. pneumophila. One reported clinical case of ciprofloxacin-resistant L. pneumophila is also present in the literature. 7 Data from an environmental study suggested that antibiotic resistance may not be a major issue as all 82 isolates of L. pneumophila tested were shown to be susceptible to clarithromycin, erythromycin, ciprofloxacin, pefloxacin and rifampicin. 8 It seems that antibiotics used for legionellosis continue to exhibit good activity against L. pneumophila isolates from environmental sources in European countries. Nevertheless, data describing susceptibility to antibiotics in clinical isolates of L. pneumophila are presently not well documented owing to the lack of an easy-toperform routine test. 9 The aim of this project was to apply pharmacological criteria to obtain a rational AST assessment of eight antibiotics (ampicillin, cefotaxime, ciprofloxacin, erythromycin, levofloxacin, moxifloxacin, rifampicin and tetracycline) for a collection of L. pneumophila strains isolated in England and Wales between 2007 and 2017. Owing to the intracellular nature of Legionella infection, the resulting MIC levels were analysed taking into account the known achievable intracellular levels for each antibiotic.
Materials and methods

Bacterial strains
A total of 92 L. pneumophila strains were analysed in this study. In-23-GI-C2). Briefly, strains stored at #80 C were inoculated on to Buffered Charcoal Yeast Extract (BCYE) agar (Oxoid Ltd, Basingstoke, UK) and incubated at 37 C in a humid environment for 48 h before AST. Four control strains were inoculated onto Columbia blood agar (Oxoid Ltd) tested in tandem to verify the quality control of the AST procedure: Escherichia coli (NCTC 10418), Klebsiella pneumoniae (ATCC 700603), Enterococcus faecium (H062340231) and Staphylococcus aureus (NCTC 12493).
Antibiotics
The following eight antibiotics were tested against the strains within the study: erythromycin, rifampicin, ampicillin, cefotaxime, tetracycline, levofloxacin, moxifloxacin (Sigma-Aldrich, Dorset, UK) and ciprofloxacin (PanReacApliChem, Darmstadt, Germany). Antibiotic concentration ranges are detailed in Table 1 .
MIC determination
Each of the 92 L. pneumophila isolates and the four controls were inoculated into 1 mL of Mueller-Hinton broth (Oxoid Ltd) with the addition of BCYE growth supplement (Thermo Fisher Scientific, Paisley, UK) and incubated for 48 h at 37 C without agitation. The broth culture was then adjusted to a turbidity equivalent to that of a 0.5 McFarland standard using fresh Mueller-Hinton broth plus BCYE supplement and diluted 1:20 to give a bacterial concentration of 6.5%10 5 /mL; 160 lL of each bacterial suspension was dispensed into 96-well microtitre plates. Forty microlitres of each antibiotic was then added to microtitre wells in 2-fold decreasing concentrations. A blank consisting of 200 lL of Mueller-Hinton broth plus BCYE supplement was used as a negative control. Plates were sealed and incubated for 48 h without agitation at 37 C before determining the MIC by the presence or absence of turbidity. 6 
MBC determination
For MBC determination for the Legionella isolates, 10 lL of broth from each well with viable growth above the MIC was inoculated on to BCYE agar and incubated for 48 h at 37 C in a humid environment. MBC was determined as the minimal concentration at which no visible growth was observed. 6 
Ethical approval
Ethical approval was not required, as only bacterial isolates from routine diagnostic samples were analysed. Table 1 
Results
MIC results
MBC results
The majority of isolates had MICs of erythromycin of 0.125-0.5 mg/L; the equivalent MBC was 8 or 16 mg/L, indicating a considerable elevation above MICs (Table 2) . For rifampicin, which had a uniform MIC, MBCs were spread over three dilutions. The MBC range of ciprofloxacin was the same as the MIC range, whereas for levofloxacin and moxifloxacin the MBC range was elevated by one dilution and two dilutions, respectively. The MBC range of ampicillin was elevated by one dilution and spread over to a dilution higher. Similarly, the MBC range of cefotaxime commenced two dilutions higher and extended over a further three. The MIC of tetracycline was the same as the MBC, which was the maximum concentration tested for this antibiotic (.2 mg/L).
Intracellular data from published literature
The intracellular concentrations for each antibiotic obtained from published literature (Table 3) were compared with the MIC and MBC values obtained in this study to determine the potential in vivo efficacy against L. pneumophila (Tables 1 and 2 ).
Comparison of MIC/MBC
MBCs of cefotaxime and ampicillin were relatively elevated compared with those of erythromycin, ciprofloxacin, levofloxacin and moxifloxacin. Figure 1 shows the relationship between MIC and MBC values for individual isolates to erythromycin, ciprofloxacin and levofloxacin. The MIC/MBC relationship for levofloxacin showed greater clustering than for ciprofloxacin. The MIC/MBC relationship for both levofloxacin and ciprofloxacin clustered much closer compared with that observed for erythromycin. Table 3 for literature references to estimated drug concentrations. 
0.125-2
MBC values equal to or lower than the lowest antimicrobial concentration tested for the panel are given as the lowest concentration. MBC values equal to or greater than the highest antimicrobial concentration tested for the panel are given a value one step above the highest concentration tested. Grey shading indicates the intracellular concentration of antibiotics in polymorphonuclear sites or alveolar macrophages and a greater than symbol indicates that the intracellular concentration was greater than the concentration listed in the table. See Table 3 for literature references to estimated drug concentrations. 1.1 (+0.5 SD) 13, 16 Rifampicin 7 (radiolabelled drug only) 13, 18, 21 ELF, epithelial lining fluid; RM, resident macrophage; SD, standard deviation.
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Discussion
The lack of clear guidelines to interpret L. pneumophila AST does not allow designation as susceptible or resistant to each of the eight antibiotics tested, highlighting the need for an agreed epidemiological cut-off value to be set. Massip et al. As shown in Figure 1 , there is little relationship between the MIC and MBC values of erythromycin; isolates with an MIC of 0.06 or 0.5 mg/L also had an MBC of 16 mg/L. This could be owing to the bacteriostatic nature of erythromycin; however, the presence of macrolide efflux pumps in L. pneumophila has already been described. 6 There was a positive relationship between the MICs and MBCs of ciprofloxacin, levofloxacin and moxifloxacin; as the MIC decreased so did the MBC, which may be expected given the bactericidal nature of fluoroquinolones. Close grouping of MIC/MBC data indicates a minimization of random outcomes; there appeared to be greater clustering shown for levofloxacin compared with ciprofloxacin and erythromycin. The MBC range of levofloxacin was lower than that of ciprofloxacin owing to outliers .0.06 mg/L for ciprofloxacin.
As L. pneumophila is an intracellular pathogen, antimicrobials used must be able to achieve sufficient therapeutic levels within host cells to ensure effective treatment. According to published data (Table 3 ) the concentration within bronchial secretions for erythromycin is 1.1 mg/L; the MIC range for our collection of isolates was 0.006-1 mg/L and the MBC range was 1-32 mg/L. These data suggest that the intracellular concentration of erythromycin should exceed the MIC for these isolates; however, 91 of 92 (98.9%) isolates had an MBC below the expected intracellular concentrations. A similar observation was made when cefotaxime was tested: all 92 isolates had an MIC ,0.6 mg/L, whereas 26 of 92 (28%) isolates had an MBC below the level achievable within bronchial secretions. The ampicillin concentration found within bronchial secretions was 0.25 mg/L; only 4 of 92 (4.3%) isolates had an MIC below this and the MBC for all 92 isolates was 0.25 mg/L. The intracellular concentration of rifampicin into polymorphonuclear leucocytes was found to be 7 mg/L; the MIC and MBC for all 92 isolates was significantly below the levels achievable intracellularly. Similarly, the MIC and MBC values for all 92 isolates were below achievable levels found intracellularly and within bronchial secretions for ciprofloxacin, levofloxacin and moxifloxacin.
In conclusion, based on the MIC/MBC concentration when compared with achievable intracellular concentrations, ampicillin, cefotaxime and erythromycin appear less suitable for treating pneumonia caused by L. pneumophila. In contrast, the analysed L. pneumophila collection was susceptible to the levels achievable intracellularly for rifampicin, ciprofloxacin, levofloxacin and moxifloxacin, indicating that these agents should reach a therapeutic concentration within eukaryotic cells. The MIC/MBC relationship and the evident clustering shown for levofloxacin, support the current guidance for using levofloxacin as the treatment of choice for LD.
